Company Name: Cynata Therapeutics
Announcement Date: 13/09/2016
Announcement Category: Contract/Partnership
Announcement Content:
Cynata and FUJIFILM Sign Non-binding Development and Commercialisation Term Sheet
Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced the execution of a term sheet with FUJIFILM Corporation of Japan for the development and commercialisation of certain Cynata technology, including Cynataâs lead induced pluripotent stem cell (iPSC) derived therapeutic mesenchymal stem cell (MSC) product, CYP-001. Pursuant to the term sheet, the parties will work together to seek to finalise a definitive agreement. If the parties enter into a definitive agreement, Cynata expects it to be finalised in the fourth quarter of 2016.
The term sheet anticipates that, under a definitive agreement, Cynata will grant FUJIFILM an option to an exclusive, worldwide licence to market and sell Cynataâs lead MSC product for prevention and treatment of graft-versus-host disease (GvHD), as well as (a) an option to negotiate a licence for manufacturing those products, and (b) certain rights to Cynataâs proprietary Cymerus⢠technology for the prevention and treatment of other diseases.
The term sheet further anticipates that, under a definitive agreement, FUJIFILM will make a direct investment in Cynata by way of the acquisition of Cynata shares to the value of US$3 million, such shares to be priced at, in consideration for the rights granted under the agreement, a 35% premium to the 6 month VWAP as at 2 September 2016. The term sheet also contemplates Cynata receiving certain upfront and milestone payments, together with a royalty on end product sales. Entry into a definitive agreement remains subject to satisfactory completion of negotiations.
âWe are delighted to execute this term sheet with FUJIFILM, one of the most dynamic and progressive companies in the global regenerative medicine space,â said Cynata Managing Director and CEO, Dr Ross Macdonald. âThe proposed acquisition by FUJIFILM of shares in Cynata at a substantial premium is a strong vote of confidence in Cynataâs unique technology and we look forward to closing the definitive agreement in the near future.â
Participant Dial-in Numbers Continued
New Zealand Toll Free: 0800 452 795
Ireland Toll Free: 1800 948 607
Auckland Local: +64 9 929 3905
Japan Toll Free: 0066 3386 8000
Canada/USA Toll Free: 1855 624 0077
Malaysia Toll Free: 1800 816 441
China Toll Free: 1080 0140 1776
Singapore Toll Free: 800 101 2702
France Toll Free: 0800 913 734
South Africa Toll Free: 0800 984 013
Germany Toll Free: 0800 183 0918
Switzerland Toll Free: 0800 802 498
Hong Kong Toll Free: 800 968 273
Taiwan Toll Free: 0080 112 7377
India Toll Free: 000 800 100 8070
UAE Toll Free: 8000 3570 2706
Indonesia Toll Free: 007 803 321 8057
UK Toll Free: 0800 051 1453
Q&A Instructions
In order to ask a question during the Live Question and Answer Session:
Press * then 1 on your telephone keypad to enter the Q&A queue
Press * then 2 on your telephone keypad to withdraw your question
About Cynata Therapeutics (ASX: CYP)
Cynata Therapeutics Limited (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerusâ˘, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus⢠technology addresses a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus⢠utilises induced pluripotent stem cells (iPSCs) to produce a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus⢠platform provides a source of MSCs that is independent of donor limitations and provides an âoff-the-shelfâ stem cell platform for therapeutic product use, with a pharmaceutical product business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.
About Fujifilm Corporation
FUJIFILM Corporation, Tokyo, Japan is one of the major operating companies of FUJIFILM Holdings. The company brings continuous innovation and leading-edge products to a broad spectrum of industries, including: healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These are based on a vast portfolio of chemical, mechanical, optical, electronic and thin film coating technologies. The Fujifilm Group is a leader in the field of regenerative medicine. US Cellular Dynamics International, Inc., has also joined the Fujifilm Group in 2015, and Fujifilm is leveraging iPSC production technologies to create an iPSC bank that comprises iPSCs for use in researching various diseases and conditions. The decision to bring these highly innovative companies into the Group further emphasizes Fujifilmâs dedication to achieving leadership in the field of regenerative medicine and to meet unmet medical needs. For more information, please visit: www.fujifilmholdings.com.
Contacts
Dr Ross Macdonald
Chief Executive Officer
T: 0412 119 343
E: [email protected]
Dr Stewart Washer
Executive Chairman
T: 0418 288 212
E: [email protected]
Kirin Smith
Chief Operating Officer, Investor/Media Contact
T: +1 646-863-6519
E: [email protected]
Rudi Michelson
Monsoon Communications
Australia Media Contact
T: 0411 402 737
E: [email protected]
Announcement URL: http://cynata.com/wp-content/uploads/2016/09/16.09.05.Cynata-Signs-Non-Binding-Terms-Sheet-with-Fujifilm.pdf
About Cynata Therapeutics:
Cynata Therapeutics Limited is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerusâ˘, using discoveries made at the University of Wisconsin-Madison (UWM). UWM is a world-renowned leader in stem cell research, in particular for the work by Professor James Thomson's group, which included the first successful isolation of human embryonic stem cells in 1998, and the derivation of induced pluripotent stem cells (iPSCs) from human adult cells in 2007. Professor Igor Slukvin, a co-founder of Cynata, was also a member of the team that conducted UWM's pioneering iPSC research.
Cynata's Cymerus⢠platform stem cell technology is based upon extremely important and versatile stem cells known as mesenchymoangioblasts (MCAs). MCAs are a precursor of mesenchymal stem (or stromal) cells (MSCs) which are at the forefront of a new generation of treatments being investigated for such devastating diseases as osteoarthritis, Crohnâs disease and heart disease. Cynataâs proprietary technology utilizes iPSCs originating from an adult donor as the starting material for generating MCAs and in turn for manufacturing the MSC therapeutic product.
Go to Company Profile for: Cynata Therapeutics
Announcement Contact: [email protected]
